drugset / Trial / NCT01966601

A Study to Explore the Efficacy of TRV027 in Patients Hospitalized for Acute Decompensated Heart Failure

NCT01966601

Phase 2 Completed 620 enrolled Trevena Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate the overall safety and efficacy of TRV027 when administered in addition to standard of care (SOC) on mortality, morbidity, dyspnea, and length of stay in patients hospitalized with Acute Decompensated Heart Failure (ADHF).

Timeline

Start
2013-12
Primary completion
2016-03
Completion
2016-09

Drugs

EvaluationDrugModalityDoseRoute
Subject TRV120027 Peptide Intravenous

Indications